Clinical Trials

    Multicenter Phase II Trial of Durvalumab (MEDI4736) With Trastuzumab and Pertuzumab Combination in HER2-Enriched and HER2-Amplified Breast Cancer (DTP Trial)

    Investigator: Polly Niravath

    Study Coordinator: Jawairia Jawed

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT03820141

    Phone: 346.356.3603

    Protocol Number: Pro00020917

    Description


    The purpose of this research study is to test the safety and effectiveness of using durvalumab with trastuzumab and pertuzumab in participants with human epidermal growth factor receptor 2 (HER2)-enriched breast cancer.